Please assess the completion status of the following clinical trial:

Trial Title: Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Primary phase:~* Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* A male or female between, and including, 12 and 18 months of age at the time of vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.~* Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.~Long-term persistence phase:~- Having participated in the vaccination study 106445~Exclusion Criteria:~For the primary vaccination phase:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.~* Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.~* Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.~* Previous administration of a booster dose of Hib vaccine.~* Previous vaccination against measles, mumps, rubella.~* History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.~* Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of neurological disorders or more than one episode of febrile convulsion.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~Additional exclusion criteria for the long-term persistence phase: to be checked each year.~* Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.~* History of H. influenzae type b, meningococcal serogroup C diseases.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Meningitec + Hiberix Group (Type: ACTIVE_COMPARATOR): Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
- Menitorix Group (Type: EXPERIMENTAL): Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).